FDA
approval
· 2025-10-29
FDA Approved: DELSTRIGO — Supplemental Application (Merck Sharp & Dohme LLC)
Summary
The FDA approved a supplemental application for DELSTRIGO, a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil fumarate, from Merck Sha…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for DELSTRIGO (DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE)